Drug Development & Approvals

BioPharma: New Treatments on the Horizon

Track drug developments, understand FDA approvals, and learn what new treatments mean for you — all explained in patient-friendly language.

Recent FDA Approvals

NEW APPROVALDecember 2024

Leqembi (lecanemab) - Alzheimer's Disease

First drug proven to slow cognitive decline in early Alzheimer's. Reduces amyloid plaques in the brain.

Manufacturer:Eisai/Biogen
Est. Cost:$26,500/year
Available:Now at specialty centers
Learn More
NEW APPROVALNovember 2024

Zurzuvae (zuranolone) - Postpartum Depression

First oral treatment specifically for postpartum depression. Works in as little as 3 days.

Manufacturer:Sage/Biogen
Treatment:14-day course
Available:By prescription
Learn More

Pipeline Watch: Coming Soon

Phase 3 - Cancer

CAR-T for Solid Tumors

New CAR-T therapies showing promise against previously untreatable solid tumors.

Expected:Q2 2025

Phase 3 - Diabetes

Weekly Insulin Alternative

Once-weekly injection could replace daily insulin for Type 2 diabetes patients.

Expected:Q3 2025

Phase 3 - Rare Disease

Gene Therapy for SMA

One-time treatment could halt progression of spinal muscular atrophy.

Expected:Q1 2025

Get Drug Development Updates

Weekly updates on drug approvals, pipeline progress, and what new treatments mean for patients.